Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is based in Alpharetta, Georgia.…
Dogwood Announces $5 Million Private Placement with CK Life Sciences Int’l., (Holdings) Inc.
Dogwood Therapeutics (NASDAQ: DWTX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 1.035 USD on 20 November 2026, down 80.3% over 52 weeks. Its 52-week range is 0.9010 USD to 7.044 USD: the price is 85.3% below the high and 14.9% above the low.
Its market capitalisation is 39.57M USD.
Dogwood Therapeutics reports return on equity of -45.7%.
It holds more cash than debt, a net cash position of 4.83M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.